All data are based on the daily closing price as of December 3, 2024
c

Celltrion Healthcare

091990.KQ
This stock is delisted

About

Celltrion Healthcare Co., Ltd. engages in the manufacture, processing, and sale of biosimilar and biological medicines to patients around the world. Its products include Remsima, a monoclonal antibody biosimilar that is used for rheumatoid arthritis, ankylosing spondylitis, ulcerative colitis, adult Crohn's disease, Crohn's disease in children, psoriasis, and psoriatic arthritis; Truxima, which is used for lymphoma, chronic lymphocytic leukemia, Wegener's granulomatosis and microscopic polyangiitis, and rheumatoid arthritis; Herzuma that is used for metastatic breast cancer, early breast cancer, and metastatic gastric cancer; and Remsima SC, which is used for rheumatoid arthritis. The company was formerly known as Nexol, Inc. and changed its name to Celltrion Healthcare Co., Ltd. in March 2009. Celltrion Healthcare Co., Ltd. was founded in 1999 and is headquartered in Incheon, South Korea. As of December 28, 2023, Celltrion Healthcare Co., Ltd. operates as a subsidiary of Celltrion, Inc..
  • Symbol
    091990.KQ
  • Exchange
    KQ
  • Isin
    KR7091990002
  • Country
    South Korea
  • Sector
    N/A
  • Industry
    N/A
  • CEO
    Hyoung Ki Kim
  • Headquarter
    Incheon
  • Web site
    https://www.celltrionhealthcare.com
Jakota Newsletter

Stay ahead in the JAKOTA stock markets with our roundup of vital insights

Icon scroll to top